Infecção por yersinia

World Health Organization. WHO guidelines for plague management. May 2021 [internet publication].Texto completo

Nelson CA, Meaney-Delman D, Fleck-Derderian S, et al. Antimicrobial treatment and prophylaxis of plague: recommendations for naturally acquired infections and bioterrorism response. MMWR Recomm Rep. 2021 Jul 16;70(3):1-27.Texto completo  Resumo

1. World Health Organization. WHO guidelines for plague management. May 2021 [internet publication].Texto completo

2. Nelson CA, Meaney-Delman D, Fleck-Derderian S, et al. Antimicrobial treatment and prophylaxis of plague: recommendations for naturally acquired infections and bioterrorism response. MMWR Recomm Rep. 2021 Jul 16;70(3):1-27.Texto completo  Resumo

3. Naktin J, Beavis KG. Yersinia enterocolitica and Yersinia pseudotuberculosis. Clin Lab Med. 1999 Sep;19(3):523-36. Resumo

4. Cover TL, Aber RC. Yersinia enterocolitica. N Engl J Med. 1989 Jul 6;321(1):16-24. Resumo

5. Taccetti G, Trapani S, Ermini M, et al. Reactive arthritis triggered by Yersinia enterocolitica: a review of 18 pediatric cases. Clin Exp Rheumatol. 1994 Nov-Dec;12(6):681-4. Resumo

6. World Health Organization. Plague manual: epidemiology, distribution, surveillance and control. Geneva, Switzerland: World Health Organization; 1999.Texto completo

7. Kool JL. Risk of person-to-person transmission of pneumonic plague. Clin Infect Dis. 2005 Apr 15;40(8):1166-72.Texto completo  Resumo

8. World Health Organization. Plague - Madagascar. Oct 2021 [internet publication].Texto completo

9. World Health Organization. Plague. Jul 2022 [internet publication].Texto completo

10. World Health Organization. Weekly epidemiological record. February 2016 [internet publication].Texto completo

11. World Health Organization. Plague outbreak Madagascar: external situation report 14. December 2017 [internet publication].Texto completo

12. Koirala J. Plague: disease, management, and recognition of act of terrorism. Infect Dis Clin North Am. 2006 Jun;20(2):273-87. Resumo

13. Centers for Disease Control and Prevention. Nationally notifiable infectious diseases andconditions, United States: weekly tables. 2022 [internet publication].Texto completo

14. Centers for Disease Control and Prevention. Notes from the field: diagnosis and investigation of Pneumonic Plague during a respiratory disease pandemic — Wyoming, 2021. Jun 2022 [internet publication].Texto completo

15. Craven RB, Maupin GO, Beard ML, et al. Reported cases of human plague infections in the United States, 1970-1991. J Med Entomol. 1993 Jul;30(4):758-61. Resumo

16. Gage KL, Dennis DT, Orloski KA, et al. Cases of cat-associated human plague in the Western US, 1977-1998. Clin Infect Dis. 2000 Jun;30(6):893-900.Texto completo  Resumo

17. Centers for Disease Control and Prevention. Red blood cell transfusions contaminated with Yersinia enterocolitica: United States, 1991-1996, and initiation of a national study to detect bacteria-associated transfusion reactions. MMWR Morb Wkly Rep. 1997 Jun 20;46(24):553-5. Resumo

18. Marder Mph EP, Griffin PM, Cieslak PR, et al. Preliminary incidence and trends of infections with pathogens transmitted commonly through food - Foodborne Diseases Active Surveillance Network, 10 US sites, 2006-2017. MMWR Morb Mortal Wkly Rep. 2018 Mar 23;67(11):324-8.Texto completo  Resumo

19. Merilahti-Palo R, Lahesmaa R, Granfors K, et al. Risk of Yersinia infection among butchers. Scand J Infect Dis. 1991;23(1):55-61. Resumo

20. Prentice MB, Rahalison L. Plague. Lancet. 2007 Apr 7;369(9568):1196-207. Resumo

21. Tsui PY, Tsai HP, Chiao DJ, et al. Rapid detection of Yersinia pestis recombinant fraction 1 capsular antigen. Appl Microbiol Biotechnol. 2015;99:7781-9. Resumo

22. Pan NJ, Brady MJ, Leong JM, et al. Targeting type III secretion in Yersinia pestis. Antimicrob Agents Chemother. 2009 Feb;53(2):385-92.Texto completo  Resumo

23. World Health Organization. Plague. October 2017 [internet publication].Texto completo

24. Metchock B, Lonsway DR, Carter GP, et al. Yersinia enterocolitica: a frequent seasonal stool isolate from children at an urban hospital in the southeast United States. J Clin Microbiol. 1991 Dec;29(12):2868-9.Texto completo  Resumo

25. Ostroff SM, Kapperud G, Hutwagner LC, et al. Sources of sporadic Yersinia enterocolitica infections in Norway: a prospective case-control study. Epidemiol Infect. 1994 Feb;112(1):133-41. Resumo

26. Centers for Disease Control and Prevention. Plague: resources for clinicians. Feb 2022 [internet publication].Texto completo

27. Boulanger LL, Ettestad P, Fogarty JD, et al. Gentamicin and tetracyclines for the treatment of human plague: review of 75 cases in New Mexico, 1985-1999. Clin Infect Dis. 2004 Mar 1;38(5):663-9.Texto completo  Resumo

28. World Health Organization. Operational guidelines on plague surveillance, diagnosis, prevention and control. 2010 [internet publication].Texto completo

29. Garcia E, Elliott JM, Ramanculov E, et al. The genome sequence of Yersinia pestis bacteriophage phiA1122 reveals an intimate history with the coliphage T3 and T7 genomes. J Bacteriol. 2003 Sep;185(17):5248-62.Texto completo  Resumo

30. Kachoris M, Ruoff KL, Welch K, et al. Routine culture of stool specimens for Yersinia enterocolitica is not a cost-effective procedure. J Clin Microbiol. 1988 Mar;26(3):582-3.Texto completo  Resumo

31. Jullien S, Dissanayake HA, Chaplin M. Rapid diagnostic tests for plague. Cochrane Database Syst Rev. 2020 Jun 26;6:CD013459.Texto completo  Resumo

32. Alsofrom DJ, Mettler FA Jr, Mann JM. Radiographic manifestations of plague in New Mexico, 1975-1980: a review of 42 proved cases. Radiology. 1981 Jun;139(3):561-5. Resumo

33. Maki-Ikola O, Heesemann J, Toivanen A, et al. High frequency of Yersinia antibodies in healthy populations in Finland and Germany. Rheumatol Int. 1997 Jun;16(6):227-9. Resumo

34. Boisier P, Rahalison L, Rasolomaharo M, et al. Epidemiologic features of four successive annual outbreaks of bubonic plague in Mahajanga, Madagascar. Emerg Infect Dis. 2002 Mar;8(3):311-6.Texto completo  Resumo

35. Ratsitorahina M, Chanteau S, Rahalison L, et al. Epidemiological and diagnostic aspects of the outbreak of pneumonic plague in Madagascar. Lancet. 2000 Jan 8;355(9198):111-3. Resumo

36. Centers for Disease Control and Prevention. Plague (Yersinia pestis): 2020 case definition. April 2021 [internet publication].Texto completo

37. Godfred-Cato S, Cooley KM, Fleck-Derderian S, et al. Treatment of human plague: a systematic review of published aggregate data on antimicrobial efficacy, 1939-2019. Clin Infect Dis. 2020 May 21;70(70 Suppl 1):S11-9.Texto completo  Resumo

38. European Medicines Agency. Quinolone- and fluoroquinolone-containing medicinal products. Mar 2019 [internet publication].Texto completo

39. US Food and Drug Administration. FDA reinforces safety information about serious low blood sugar levels and mental health side effects with fluoroquinolone antibiotics; requires label changes. Jul 2018 [internet publication].Texto completo

40. US Food and Drug Administration. FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients. December 2018 [internet publication].Texto completo

41. Nelson CA, Fleck-Derderian S, Cooley KM, et al. Antimicrobial treatment of human plague: a systematic review of the literature on individual cases, 1937-2019. Clin Infect Dis. 2020 May 21;70(70 Suppl 1):S3-10.Texto completo  Resumo

42. Kugeler KJ, Mead PS, Campbell SB, et al. Antimicrobial treatment patterns and illness outcome among united states patients with plague, 1942-2018. Clin Infect Dis. 2020 May 21;70(70 Suppl 1):S20-6.Texto completo  Resumo

43. Fleck-Derderian S, Nelson CA, Cooley KM, et al. Plague during pregnancy: a systematic review. Clin Infect Dis. 2020 May 21;70(70 Suppl 1):S30-6.Texto completo  Resumo

44. Yu PA, Tran EL, Parker CM, et al. Safety of antimicrobials during pregnancy: a systematic review of antimicrobials considered for treatment and postexposure prophylaxis of plague. Clin Infect Dis. 2020 May 21;70(70 Suppl 1):S37-50.Texto completo  Resumo

45. Yefet E, Schwartz N, Chazan B, et al. The safety of quinolones and fluoroquinolones in pregnancy: a meta-analysis. BJOG. 2018 Aug;125(9):1069-76. Resumo

46. Hoogkamp-Korstanje JA. Antibiotics in Yersinia enterocolitica infections. J Antimicrob Chemother. 1987 Jul;20(1):123-31. Resumo

47. Gayraud M, Scavizzi MR, Mollaret HH, et al. Antibiotic treatment of Yersinia enterocolitica septicemia: a retrospective review of 43 cases. Clin Infect Dis. 1993 Sep;17(3):405-10. Resumo

48. Shane AL, Mody RK, Crump JA, et al. 2017 Infectious Diseases Society of America clinical practice guidelines for the diagnosis and management of infectious diarrhea. Clin Infect Dis. 2017 Nov 29;65(12):e45-80.Texto completo  Resumo

49. Centers for Disease Control and Prevention. CDC Yellow Book: health information for international travel - 2024. Section 5: travel-associated infections & diseases - yersiniosis. May 2023 [internet publication]​.Texto completo

50. US Food and Drug Agency. FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients. Dec 2018 [internet publication].Texto completo

51. Saebo A, Lassen J. Survival and causes of death among patients with Yersinia enterocolitica infection: a Norwegian 10-year follow-up study on 458 hospitalized patients. Scand J Infect Dis. 1992;24(5):613-7. Resumo

52. Leirisalo-Repo M, Suoranta H. Ten-year follow-up study of patients with Yersinia arthritis. Arthritis Rheum. 1988 Apr;31(4):533-7. Resumo